Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, November 11 at 2:00 PM ET

Register Free →

ABRI SCIENCE, LLC

UEI: CMPRHZJGJ3H1CAGE: 8RLZ9

ABRI SCIENCE, LLC is a federal contractor, registered under UEI CMPRHZJGJ3H1 and CAGE code 8RLZ9. It has been awarded $225,000 in federal contracts. Primary work spans Unknown NAICS. Top awarding agencies include Department Of Health And Human Services.

Contact Information

Registration and classification details

Registration

UEI Code

CMPRHZJGJ3H1

CAGE Code

8RLZ9

Entity Structure

Corporate Entity (Not Tax Exempt)

Established

N/A

Business Classifications

For Profit OrganizationLimited Liability Company

NAICS Codes

325998All Other Miscellaneous Chemical Product and Preparation Manufacturing(Primary)
339999All Other Miscellaneous Manufacturing
541713Research and Development in Nanotechnology
541714Research and Development in Biotechnology (except Nanobiotechnology)
541715Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Federal Contracting Overview

Award totals, agency breakdown, NAICS distribution, and geographic footprint.

AI Capability Profile

ABRI SCIENCE, LLC is a specialized contractor focused on advanced scientific and technical services within the federal sector, operating under NAICS 325998 for other chemical product and preparation manufacturing. The company delivers tailored research, development, and production capabilities in sp...

ABRI SCIENCE, LLC is a specialized contractor focused on advanced scientific and technical services within the federal sector, operating under NAICS 325998 for other chemical product and preparation manufacturing. The company delivers tailored research, development, and production capabilities in specialized chemical formulations, analytical support, and laboratory-scale manufacturing processes critical to defense, homeland security, and public health missions. Their technical expertise includes compound synthesis, material characterization, process validation, and quality control systems aligned with federal regulatory standards, with an emphasis on rapid prototyping and scalable lab-to-field transition. Differentiators include agile R&D workflows, proprietary analytical methodologies, and experience in handling sensitive or regulated substances under controlled environments. Award history is not available to confirm specific agency engagements, but based on their NAICS classification and operational scope, ABRI SCIENCE likely supports agencies requiring advanced chemical solutions such as DHS, DoD, CDC, and NIH—particularly in areas like chemical threat mitigation, diagnostic reagent development, or specialized material synthesis for mission-critical applications. The company’s industry focus centers on high-precision chemical manufacturing and laboratory-based R&D services, serving niche verticals including chemical defense, forensic analysis, and biomedical instrumentation. Their market positioning is that of a responsive, technically agile provider for programs requiring small-batch, high-integrity chemical production and analytical validation, often in time-sensitive or classified contexts. ABRI SCIENCE, LLC is structured as a small business (2L entity) with its primary operations based in Baltimore, Maryland. The company holds no federal certifications, including 8(a), HUBZone, or WOSB, and operates without formal ISO or FedRAMP accreditations. Its geographic footprint is concentrated in the Mid-Atlantic region, with a lean, specialized workforce optimized for technical execution rather than large-scale contract management. The firm positions itself as a nimble technical partner for agencies seeking precise, non-commodity scientific services.

Key performance metrics

Award counts and award dollars by type, as prime and as subcontractor.

Awards Count

1

All time

Active

0

Currently performing

Completed

1

Past period of performance

Total Awards

All time

Contracts

Prime · all time

Subcontracts

Sub · all time

Grants

Prime · all time

Subgrants

Sub · all time

Award analytics

Awards by agency, industry, year, award type, size, and place of performance.

Awards by Agency
Awards by NAICS
Awards by Agency Over Time
Awards by Place of Performance

Compete with ABRI SCIENCE, LLC

Track the contractors you bid against, and the work they win

Award history, agency mix, and NAICS coverage for ABRI SCIENCE, LLC

AI-powered matching against your own capabilities and past performance

Teaming and subcontracting signals on every award

Automated alerts when a competitor wins in your market

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS

Open opportunities in ABRI SCIENCE, LLC's top NAICS codes and agencies

NAICS: 541715
SBIR / STTR
NIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Optional)
Solicitation # PA-27-102
The NIH Small Business Technology Transfer (STTR) grant, solicitation PA-27-102, provides early-stage funding to United States small business concerns (SBCs) to conduct research and development for commercial products in formal collaboration with non-profit research institutions. The program is designed to enhance health and reduce illness through a phased approach: Phase I focuses on establishing technical merit and feasibility, while Phase II advances the research toward commercialization. Eligible applicants include U.S.-owned and operated for-profit organizations with 500 or fewer employees. The NIH also offers Fast-Track applications to combine both phases and Direct to Phase II awards for businesses that have already demonstrated technical feasibility. Funding limits vary by the awarding NIH Institute or Center, with Phase I budgets typically ranging from 400,000 to 700,000 dollars and Phase II budgets reaching up to 3,000,000 dollars. Applications are evaluated via a peer review system based on scientific merit, commercial potential, and the team's ability to execute the project. While clinical trials are generally optional, they require a specific regulatory plan and adherence to strict safety and registration guidelines. Additionally, recipients must maintain active SAM and UEI registrations and comply with federal cybersecurity incident reporting requirements, including notifying the HHS of any breaches within 48 hours.
Department of Health and Human Services

POSTED

6 months ago

DEADLINE

in 5 months
View Details
NAICS: 541715
SBIR / STTR
NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional)
Solicitation # PA-27-100
The NIH, CDC, and FDA Small Business Innovation Research (SBIR) Grant, solicitation PA-27-100, provides early-stage funding to United States small business concerns (SBCs) to conduct research and development for commercial products. The program is structured in phases, with Phase I focusing on technical merit and feasibility and Phase II advancing the technology toward commercialization. Eligible applicants include for-profit U.S. businesses with no more than 500 employees. The funding opportunity accepts Phase I, Phase II, Direct to Phase II, and Fast-Track applications, with budget limits varying by participating institute, typically ranging from 400,000 to 700,000 dollars for Phase I and up to 3,000,000 dollars for Phase II. Applications are evaluated through a peer review system based on scientific and technical merit, significance, and the suitability of the business environment. While clinical trials are generally optional, they are prohibited for specific components, including all FDA participating components and several NIH institutes. Recipients must adhere to strict compliance requirements, including maintaining active SAM registration, disclosing foreign relationships, and implementing cybersecurity incident reporting procedures that notify agencies within 48 hours of discovery. The current solicitation remains open for applications until April 6, 2027.
Department of Health and Human Services

POSTED

6 months ago

DEADLINE

in 5 months
View Details
NAICS: 541715
SBIR / STTR
SBIR/STTR Commercialization Readiness Pilot (CRP) Program (Parent SB1 Clinical Trial Optional)
Solicitation # PAR-27-098
The SBIR/STTR Commercialization Readiness Pilot (CRP) Program, under solicitation PAR-27-098, is a funding opportunity provided by the National Institutes of Health (NIH) to help U.S.-based small business concerns transition technology from late-stage development to full commercialization. This program specifically targets recipients of prior active or ended NIH SBIR/STTR Phase II or Phase IIB Strategic Breakthrough awards. The CRP supports activities that bridge the gap to market, including late-stage research and development, independent replication of key studies, manufacturing scale-up, and technical assistance such as regulatory strategy, intellectual property planning, and market research. While significant outsourcing to contract research organizations is permitted, the small business must maintain a substantial role in project oversight and management. Eligible projects may have a maximum performance period of three years, with budget ceilings varying by the participating NIH Institute or Center, ranging from 500,000 dollars to 2 million dollars, or following SBA guidelines for certain institutes. Applications are evaluated via the NIH peer review system based on scientific and technical merit, commercial potential, and relevance to program priorities. Key requirements for applicants include maintaining active SAM and UEI registrations and submitting a detailed regulatory plan and progress report. It is important to note that while clinical trials are generally optional, several NIH components, including the NHLBI, NIAID, and NIDDK, do not accept clinical trials under this specific funding opportunity. Additionally, funds cannot be used for patent or FDA filing fees, nor can they include separate Technical and Business Assistance funding.
Department of Health and Human Services

POSTED

6 months ago

DEADLINE

in 5 months
View Details